| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |